Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures to ensure product quality before resuming supplies.
In its statement, Dr Reddy’s emphasised that there is no impact on patient safety or on the product’s existing global regulatory filings, indicating that the quality deviation was identified before affected batches reached patients. The drugmaker did not specify how long the supply disruption is expected to last and has not disclosed further technical details beyond confirming that some batches failed to meet predefined quality specifications.
News of the delay prompted a sharp market reaction, with Dr Reddy’s shares falling between 6 and 7 per cent in trading following the announcement. Investors are closely watching for updates on the timeline for normalisation of semaglutide production, as the drug is a key component of the company’s portfolio in the fast-growing metabolic and diabetes segment.
The episode underscores the critical importance of stringent quality controls in complex peptide-based therapies like semaglutide, which are increasingly used worldwide for diabetes and obesity management. While Dr Reddy’s has reassured that patient safety remains unaffected, the company’s focus in the near term will be on resolving the API-related issue, restoring supply continuity and maintaining confidence among regulators, prescribers and patients.
